OREM, Utah, Feb. 05, 2026 (GLOBE NEWSWIRE) -- SunPower Inc. (“SunPower,” the “Company,” or Nasdaq: “SPWR”) a solar technology, services, and installation company, today announced that on February 2, 2026 it made inducement grants to two key employees of Cobalt Power Systems, Inc. (“Cobalt”) as a material inducement to employment with SunPower upon SunPower’s acquisition of Cobalt. The inducement grants consist of time-based restricted stock units (“RSUs”) for a total of 850,000 shares of SunPower common sto ...

Core Viewpoint - Anonymous Intelligence Company Inc. has granted restricted share units and stock options to its directors and officers as part of its Equity Incentive Plan to align their interests with those of shareholders and support the company's growth [1][3]. Equity Awards Details - The company granted a total of 600,000 stock options and 790,000 restricted share units to its directors and officers [2]. - Each stock option is exercisable for one common share at an exercise price of $0.19 per share for a period of five years from the grant date [2]. Company Overview - Anonymous Intelligence Company Inc. focuses on developing decentralized network infrastructure, data storage technology, and privacy-enhancing AI tools [5]. - The company aims to empower individuals and businesses by providing confidence in technology through its innovative solutions while prioritizing user privacy and data security [5].

Core Viewpoint - Optimi Health Corp. is implementing equity compensation and marketing initiatives to support its growth strategy and enhance market awareness [1] Equity Incentive Grants - The company has approved the grant of 850,000 stock options and 555,000 restricted share rights to directors, officers, employees, and key individuals [2] - The stock options are exercisable for five years at an exercise price of $0.50 per common share, while the restricted share rights will convert into common shares without additional consideration [3] Marketing and Sponsored Research Initiatives - Optimi has entered into a research sponsorship agreement with Diamond Equity Research LLC to provide independent research coverage, including an initiation report and financial valuation model [4] - Research coverage will be distributed through various financial and social media platforms such as FactSet, LinkedIn, Yahoo Finance, and Google Finance [5] Marketing and Investor Awareness Services - The company has engaged Native Ads Inc. for investor awareness and promotional services, with a digital media campaign set to begin in Q1 2026 and last up to 24 months [6] - A budget of up to US$350,000 has been approved for the digital advertising campaign aimed at increasing awareness of the company's MDMA and psilocybin products [7][8] Company Overview - Optimi Health Corp. is a GMP-compliant pharmaceutical drug manufacturer licensed by Health Canada, operating from two facilities in British Columbia [9]

Core Viewpoint - Matador Technologies Inc. has granted 631,818 restricted share units (RSUs) to certain officers and consultants as part of its Omnibus Equity Incentive Plan, with a 12-month vesting period starting January 8, 2026 [1] Group 1 - The total number of RSUs granted is 631,818 [1] - The RSUs are part of the company's Omnibus Equity Incentive Plan [1] - The vesting period for the RSUs is set for 12 months, beginning on January 8, 2026 [1]

Core Viewpoint - Cytokinetics granted stock options and restricted stock units (RSUs) to new employees as an inducement for their employment, reflecting the company's strategy to attract talent in the biopharmaceutical sector [1][3]. Summary by Sections Stock Options and RSUs - On December 15, 2025, Cytokinetics granted stock options to purchase 21,399 shares and 14,422 RSUs to 10 new employees [1]. - The RSUs will vest over 3 years, with 40% vesting on the first anniversary, another 40% on the second anniversary, and the final 20% on the third anniversary, contingent on continued employment [2]. - The stock options have an exercise price of $62.16 per share, equal to the closing price on the grant date, and will vest over 4 years, with 1/4th vesting on the first anniversary and the remainder vesting monthly over the next 36 months [2]. Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [4]. - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive Phase 3 trial results for obstructive hypertrophic cardiomyopathy [4]. - Other products in development include omecamtiv mecarbil for heart failure with severely reduced ejection fraction, ulacamten for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy and other muscle function impairments [4].

Group 1 - Cygnus Metals Limited has issued 3,000,000 additional performance rights to CEO Nicholas Kwong under its Omnibus Equity Incentive Plan following management changes [1] - Mr. Ernest Mast transitioned from Managing Director to Non-Executive Director and forfeited 6,000,000 performance rights as part of this transition [1] - The performance rights vest upon the successful completion of specific key performance objectives by July 11, 2028, and each vested right is exercisable for one fully paid ordinary share [3] Group 2 - The objective of the Omnibus Equity Incentive Plan is to promote the long-term success of the Company and align the interests of eligible persons with those of the Company [4] - Shareholders approved the Plan and the issuance of performance rights to directors at the annual general meeting on May 14, 2025 [2] - Cygnus Metals is focused on advancing its Chibougamau Copper-Gold Project in Quebec and has significant lithium assets in the James Bay district, along with REE and base metal projects in Western Australia [6]

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - Magma Silver Corp. (TSXV: MGMA) (OTCQB: MAGMF) (FSE: BC21) (WKN: A411DV) (the "Company" or "Magma") announced that its board of directors has approved the grant of a total of 50,000 incentive stock options (the "Stock Options") to certain of its directors, officers, consultants, and employees pursuant to the Company's Stock Option Plan. Such Stock Options are exercisable into Common Shares at an exercise price of $0.27 per share for a peri ...

VANCOUVER, British Columbia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Sable Resources Ltd. (“Sable” or the “Company”) (TSXV: SAE | OTCQB: SBLRF) is pleased to announce that the shareholders of the Company provided near unanimous approval of a new omnibus equity incentive plan (the “Equity Incentive Plan”) at the Company’s annual general and special meeting of shareholders held earlier today (the “Meeting”). All other matters advanced at the Meeting, including setting the board at five members, re-election of direc ...

Core Points - NexMetals Mining Corp. has granted annual equity incentive awards to directors, officers, employees, and consultants under its Omnibus Equity Incentive Plan [1][3] - The Board approved the grant of 332,512 restricted share units (RSUs), with 287,512 RSUs priced at $7.60 each, reflecting a 55% premium over the closing share price on November 17, 2025 [2] - An additional 45,000 RSUs were granted at a price of $8.80 each, representing a 79% premium to the closing share price [2] - The company also granted 46,600 deferred share units (DSUs) to directors at a price of $7.60 each, which will be payable in cash [3] - The equity incentive grants aim to align the interests of stakeholders with those of shareholders and support long-term retention and performance objectives [3] Company Overview - NexMetals Mining Corp. focuses on the redevelopment of previously producing copper, nickel, and cobalt resource mines in Botswana [5] - The company emphasizes governance through transparent accountability and open communication [6] - The team at NexMetals has extensive experience in mine discovery and development, with senior members averaging over 20 years in geology, engineering, operations, and project development [6]

Core Insights - CMOC Group reported record high results for 3Q25, with net profit attributable to shareholders growing 73% YoY to Rmb14.3 billion, driven by increased sales volume and prices of metal products [1] Financial Performance - In 1–3Q25, revenue decreased by 6% YoY to Rmb145.5 billion, while net profit attributable to shareholders increased by 73% YoY to Rmb14.3 billion [1] - For 3Q25, revenue fell 2% YoY but rose 4% QoQ to Rmb50.7 billion, with net profit attributable to shareholders growing 96% YoY and 19% QoQ to Rmb5.6 billion [1] - Copper and cobalt output rose 14% and 4% YoY, respectively, in 1–3Q25, meeting 86% and 80% of the firm's annual guidance [1] Sales and Pricing - Copper sales volume increased by 11% YoY, while cobalt sales volume fell by 36% YoY in 1–3Q25, primarily due to a cobalt export ban from the Democratic Republic of the Congo [1] - Average prices for copper, cobalt, molybdenum, tungsten, niobium, and phosphorus rose by 4%, 15%, 7%, 30%, 8%, and 20% YoY, respectively, in 1–3Q25 [1] Strategic Developments - The firm announced the Phase II KFM project, targeting an annual copper production capacity of 800,000 to 1 million tons, expected to start production in 2027 [2] - A significant equity incentive plan was proposed to issue 393 million H shares to retain core talent [3] Market Dynamics - Tightening supply and demand dynamics are expected to push up cobalt prices, with the DRC's cobalt quota for 2026/27 accounting for 44% of its 2024 output [4] - The company holds the highest local market quota for cobalt, which is projected to account for 32% of the total local quota and 29% of its 2024 sales volume [4] Financial Forecasts and Valuation - Earnings forecasts for 2025 and 2026 have been raised by 26.6% and 32.0%, respectively, to Rmb20.67 billion and Rmb27.25 billion [5] - A-share stock is trading at 17.4x 2025e and 13.2x 2026e P/E, while H-share stock is trading at 15.4x 2025e and 11.5x 2026e P/E [5] - Target prices for A-shares and H-shares have been raised by 41% to Rmb20.4 and HK$19.7, respectively, implying a 21.6% upside [5]